Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA)

American Journal of Transplantation

Volumn 11, Issue 1, 2011, Pages 56-65

  Loupy, A ^a,b,c   Hill, G S ^d   Suberbielle, C ^e   Charron, D ^e   Anglicheau, D ^a,b   Zuber, J ^a,b   Timsit, M O ^a   Duong, J P ^b,d   Bruneval, P ^b,d   Vernerey, Dewi ^c   Empana, J P ^b,c   Jouven, X ^b,c   Nochy, D ^d   Legendre, C H ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e SAINT LOUIS HOSPITAL   (France)

Author keywords

Chronic graft deterioration; donor specific antibodies; humoral allograft rejection

Indexed keywords

BASILIXIMAB; COMPLEMENT COMPONENT C4D; CYCLOSPORIN; HUMAN IMMUNOGLOBULIN; KIDNEY ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CLINICAL PROTOCOL; COMPLEMENT DEPOSITION; GLOMERULOPATHY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MICROCIRCULATION; PRIORITY JOURNAL; SCORING SYSTEM;

ADULT; AGED; ANTIBODIES; BIOPSY; COMPLEMENT C4B; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; MICROCIRCULATION; MIDDLE AGED; PEPTIDE FRAGMENTS;

EID: 78650867494     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03364.x     Document Type: Article

References (29)

1. Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O,. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966; 2: 662-665.
2. Halloran PF, Schlaut J, Solez K, Srinivasa NS,. The significance of the anti-class I response: II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992; 53: 550-555.
3. Feucht HE, Felber E, Gokel MJ, et al,. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991; 86: 464-470.
4. Loupy A, Suberbielle-Boissel C, Hill GS, et al,. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561-2570.
5. Sis B, Halloran PF,. Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Curr Opin Organ Transplant 2010; 15: 42-48.
6. Solez K, Colvin RB, Racusen LC, et al,. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760. (Pubitemid 351347767)
7. Einecke G, Sis B, Reeve J, et al,. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520-2531.
8. Haas M, Montgomery RA, Segev DL, et al,. Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 2007; 7: 576-585.
9. Gloor JM, Cosio FG, Rea DJ, et al,. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006; 6: 1841-1847.
10. Lefaucheur C, Nochy D, Andrade J, et al,. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9: 1099-1107.
11. Solez K, Colvin RB, Racusen LC, et al,. Banff '05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518-526.
12. Racusen LC, Colvin RB, Solez K, et al,. Antibody-mediated rejection criteria-An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
13. Colvin RB,. Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18: 1046-1056.
14. Watschinger B, Pascual M,. Capillary C4d deposition as a marker of humoral immunity in renal allograft rejection. J Am Soc Nephrol 2002; 13: 2420-2423.
15. Haas M, Rahman MH, Racusen LC, et al,. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: Correlation with histologic findings. Am J Transplant 2006; 6: 1829-1840.
16. Crespo M, Pascual M, Tolkoff-Rubin N, et al,. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 2001; 71: 652-658.
17. Mauiyyedi S, Crespo M, Collins AB, et al,. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13: 779-787.
18. Haririan A, Kiangkitiwan B, Kukuruga D, et al,. The impact of C4d pattern and donor-specific antibody on graft survival in recipients requiring indication renal allograft biopsy. Am J Transplant 2009; 9: 2758-2767.
19. Kedainis RL, Koch MJ, Brennan DC, Liapis H,. Focal C4d+ in renal allografts is associated with the presence of donor-specific antibodies and decreased allograft survival. Am J Transplant 2009; 9: 812-819.
20. Sis B, Mengel M, Haas M, et al,. Banff '09 Meeting Report: Antibody mediated graft deterioration and implementation of Banff Working Groups. Am J Transplant 2010 (in press).
21. Mengel M, Bogers J, Bosmans JL, et al,. Incidence of C4d stain in protocol biopsies from renal allografts: Results from a multicenter trial. Am J Transplant 2005; 5: 1050-1056.
22. Kayler LK, Kiss L, Sharma V, et al,. Acute renal allograft rejection: Diagnostic significance of focal peritubular capillary C4d. Transplantation 2008; 85: 813-820.
23. Magil AB, Tinckam KJ,. Focal peritubular capillary C4d deposition in acute rejection. Nephrol Dial Transplant 2006; 21: 1382-1388.
24. Hidalgo LG, Campbell PM, Sis B, et al,. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532-2541.
25. Kaczmarek I, Deutsch MA, Kauke T, et al,. Donor-specific HLA alloantibodies: Long-term impact on cardiac allograft vasculopathy and mortality after heart transplant. Exp Clin Transplant 2008; 6: 229-235.
26. Lietz K, John R, Burke E, et al,. Immunoglobulin M-to-immunoglobulin G anti-human leukocyte antigen class II antibody switching in cardiac transplant recipients is associated with an increased risk of cellular rejection and coronary artery disease. Circulation 2005; 112: 2468-2476.
27. Bohmig GA, Exner M, Habicht A, et al,. Capillary C4d deposition in kidney allografts: A specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13: 1091-1099.
28. Gloor JM, Sethi S, Stegall MD, et al,. Transplant glomerulopathy: Subclinical incidence and association with alloantibody. Am J Transplant 2007; 7: 2124-2132.
29. Loupy A, Suberbielle-Boissel C, Zuber J, et al,. Combined post-transplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor specific antibodies: A pilot study. Transplantation 2010; 89: 1403-1410.